Related Experiment Video
Updated: Jun 27, 2025
15:15
Flow Cytometry Analysis of Immune Cells Within Murine Aortas
Published on: July 1, 2011
34.7K
Targeting immune cell recruitment in atherosclerosis
Yvonne Döring1,2,3,4, Emiel P C van der Vorst5,6,7,8, Christian Weber9,10,11,12
1Department of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. yvonne.doering@unibe.ch.
Nature Reviews. Cardiology
|April 25, 2024
Summary
Atherosclerosis involves chronic inflammation driven by leukocyte infiltration. New research explores targeted therapies to block this process, offering hope for treating cardiovascular diseases like heart attack and stroke.
Area of Science:
- Cardiovascular Research
- Immunology
- Inflammation Biology
Background:
- Atherosclerosis, a leading cause of myocardial infarction and stroke, involves chronic inflammation in arteries.
- Leukocyte infiltration into the arterial wall, triggered by hyperlipidemia, drives atherosclerotic plaque development.
- Current therapeutic strategies targeting leukocytes in atherosclerosis face challenges in clinical translation due to lack of specificity.
Purpose of the Study:
- To review recent research on receptor-ligand interactions regulating leukocyte influx in atherosclerosis.
- To explore pharmacological interventions targeting these interactions.
- To discuss mechanisms of inflammation resolution and their therapeutic potential.
Main Methods:
- Review of current literature on leukocyte trafficking in atherosclerosis.
- Analysis of pharmacological interventions targeting specific molecular pathways.
- Examination of studies investigating inflammation resolution mechanisms.
Main Results:
- Identified key receptor-ligand pairs and interactors governing leukocyte recruitment in atherosclerotic arteries.
- Highlighted the limitations of current broad-spectrum anti-leukocyte therapies.
- Discussed the potential of targeting specific molecular interactions for improved therapeutic outcomes.
Conclusions:
- Targeting specific leukocyte-endothelial interactions offers a promising strategy for atherosclerotic cardiovascular disease therapy.
- Developing tissue-specific and selective inhibition strategies is crucial for clinical translation.
- Understanding inflammation resolution pathways may reveal novel therapeutic avenues.
